A study presented for the first time today at the 3rd European Stanley Foundation Conference on Bipolar Disorder (ESFC-BD) in Freiburg, Germany, examines the use of SEROQUEL® (quetiapine fumarate) as an adjunctive medication to mood stabilizers in the treatment of acute mania in bipolar patients.
Results from this trial suggest that patients treated with SEROQUEL demonstrated a significantly greater response rate compared to the placebo group (54.3 percent and 32.6 percent, respectively).
The data are the first in a series of Phase III trials that examines the efficacy, tolerability and safety of SEROQUEL in the treatment of acute mania.(1) SEROQUEL, a product of AstraZeneca, is indicated for the treatment of schizophrenia in adults.
“The trial results suggest that SEROQUEL may be an option in treating acute mania and the psychotic symptoms often associated with it,” said Gary Sachs, MD, Harvard Medical School, and lead investigator in the study presented today.
“More patients treated with SEROQUEL experienced a full resolution of their manic symptoms compared to placebo (45.7 percent vs. 25.8 percent respectively based on the Young Mania Rating Scale (YMRS) scores).”(1)
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!